A Phase 2 interventional study of EN3835 and Placebo in Plantar Fibromatosis, sponsored by Endo USA Inc., a Keenova Therapeutics Company. Completed at 43 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-27.
Sponsored by Endo USA Inc., a Keenova Therapeutics Company (part of Keenova Therapeutics plc) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This randomized, double-blind, placebo-controlled study will evaluate the efficacy and safety of up to 2 treatments of EN3835 vs placebo in participants with plantar fibromatosis.
Endo USA Inc., a Keenova Therapeutics Company is the lead sponsor of 8 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participant will receive a maximum dose of up to 1.8mg of EN3835 injection
Biological: EN3835
Participant will receive a matched Placebo injection
Other: Placebo
Participant will receive a maximum dose of up to1.8mg of EN3835 injection
Participant will receive a matched Placebo injection
Change From Baseline to Day 57 in the Foot Function Index (FFI) Pain Subscale Score
FFI pain subscale consisted of 9 items which were scored on a scale of 0 ("None") to 4 ("Extreme") with a total score ranging from 0 to 36. Lower scores indicated better foot function, while higher scores reflected greater impairment.
Time frame: Baseline (Day 1), Day 57
Change From Baseline to Day 57 in the FFI Total Combined (Pain and Difficulty) Score
The FFI pain subscale consisted of 9 items which were scored on a scale of 0 ("None") to 4 ("Extreme") with a total score ranging from 0 to 36. The FFI difficulty subscale consisted of 9 items which were scored on a scale of 0 ("No difficulty") to 4 ("A lot of difficulty") with a total score ranging from 0 to 36. The Total Combined score of pain and difficulty comprised scores of answered items in each subscale with a maximum total score range of 0 to 72. Lower scores indicated better foot function, while higher scores reflected greater impairment.
Time frame: Baseline (Day 1), Day 57
Percentage of Participants With a Response of "Minimal Improvement", "Much Improvement" or "Very Much Improvement" (Responders) in the Clinician Global Impression of Change Scale
The responder (by foot/feet) was defined as a participant with a response of "Minimal Improvement", "Much Improvement" or "Very Much Improvement" in the CGIC Scale. All participants who withdrew early from the study were considered as non-responders. If participant was treated for both feet, then the assessment could be combined at participant level using worst case approach, if one foot response was recorded as 'Minimal Improvement' and 'Very Much Improvement' in another foot, then response was considered as 'Minimal Improvement'.
Time frame: Day 57
Change From Baseline to Day 57 in the Nodular Hardness of the Treated Nodules by Durometer Measurement
A durometer was used to measure the hardness of treated nodules, on a scale ranging from 0 to 100. Higher scores indicated a greater hardness.
Time frame: Baseline (Day 1), Day 57
| Milestone | EN3835 Group | Placebo Group |
|---|---|---|
| Started | 88 | 88 |
| Intent to treat set | 88 | 88 |
| Received at least 1 dose of study drug | 87 | 87 |
| Completed | 83 | 83 |
| Not completed | 5 | 5 |
| Withdrew: Lost to follow-up | 3 | 1 |
| Withdrew: Sponsor decision | 0 | 1 |
| Withdrew: Other | 2 | 3 |
FFI pain subscale consisted of 9 items which were scored on a scale of 0 ("None") to 4 ("Extreme") with a total score ranging from 0 to 36. Lower scores indicated better foot function, while higher scores reflected greater impairment.
| score on a scale | EN3835 Group | Placebo Group |
|---|---|---|
| Change From Baseline to Day 57 in the Foot Function Index (FFI) Pain Subscale Score | -9.844 ± 0.91 | -8.417 ± 0.89 |
The FFI pain subscale consisted of 9 items which were scored on a scale of 0 ("None") to 4 ("Extreme") with a total score ranging from 0 to 36. The FFI difficulty subscale consisted of 9 items which were scored on a scale of 0 ("No difficulty") to 4 ("A lot of difficulty") with a total score ranging from 0 to 36. The Total Combined score of pain and difficulty comprised scores of answered items in each subscale with a maximum total score range of 0 to 72. Lower scores indicated better foot function, while higher scores reflected greater impairment.
| score on a scale | EN3835 Group | Placebo Group |
|---|---|---|
| Change From Baseline to Day 57 in the FFI Total Combined (Pain and Difficulty) Score | -19.145 ± 1.893 | -16.530 ± 1.858 |
The responder (by foot/feet) was defined as a participant with a response of "Minimal Improvement", "Much Improvement" or "Very Much Improvement" in the CGIC Scale. All participants who withdrew early from the study were considered as non-responders. If participant was treated for both feet, then the assessment could be combined at participant level using worst case approach, if one foot response was recorded as 'Minimal Improvement' and 'Very Much Improvement' in another foot, then response was considered as 'Minimal Improvement'.
| Percentage of participants | EN3835 Group | Placebo Group |
|---|---|---|
| Percentage of Participants With a Response of "Minimal Improvement", "Much Improvement" or "Very Much Improvement" (Responders) in the Clinician Global Impression of Change Scale | 61 (59.0 to 78.0) | 48 (44.2 to 64.5) |
A durometer was used to measure the hardness of treated nodules, on a scale ranging from 0 to 100. Higher scores indicated a greater hardness.
| score on a scale | EN3835 Group | Placebo Group |
|---|---|---|
| Change From Baseline to Day 57 in the Nodular Hardness of the Treated Nodules by Durometer Measurement | -13.537 ± 1.76 | -7.660 ± 1.75 |
Collected over Day 1 to Day 57. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| EN3835 Group | 0/88 (0%) | 0/87 (0%) | 58/87 (66.7%) |
| Placebo Group | 0/88 (0%) | 2/87 (2.3%) | 35/87 (40.2%) |
| Event | EN3835 Group | Placebo Group |
|---|---|---|
| Colitis ulcerativeGastrointestinal disorders | 0/87 | 1/87 |
| Tendon injuryInjury, poisoning and procedural complications | 0/87 | 1/87 |
| Event | EN3835 Group | Placebo Group |
|---|---|---|
| Injection site painGeneral disorders | 39/87 | 9/87 |
| Injection site bruisingGeneral disorders | 37/87 | 2/87 |
| Injection site swellingGeneral disorders | 25/87 | 3/87 |
| NoduleGeneral disorders | 3/87 | 5/87 |
| Injection site pruritisGeneral disorders | 5/87 | 0/87 |
| Injection site oedemaGeneral disorders | 4/87 | 0/87 |
| Tendon injuryInjury, poisoning and procedural complications | 3/87 | 0/87 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/87 | 3/87 |
| COVID-19Infections and infestations | 3/87 | 0/87 |
| Injection site discomfortGeneral disorders | 2/87 | 0/87 |
The Intent to treat (ITT) population included all randomized participants.
| Age, Continuous(years) | EN3835 Group | Placebo Group | Total |
|---|---|---|---|
| Mean | 54.7 ± 10.93 | 56.3 ± 10.58 | 55.5 ± 10.75 |
| Sex: Female, Male(Participants) | EN3835 Group | Placebo Group | Total |
|---|---|---|---|
| Female | 58 | 61 | 119 |
| Male | 30 | 27 | 57 |
| Ethnicity (NIH/OMB)(Participants) | EN3835 Group | Placebo Group | Total |
|---|---|---|---|
| Hispanic or Latino | 13 | 9 | 22 |
| Not Hispanic or Latino | 74 | 77 | 151 |
| Unknown or Not Reported | 1 | 2 | 3 |
| Race (NIH/OMB)(Participants) | EN3835 Group | Placebo Group | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 |
| Black or African American | 16 | 17 | 33 |
| White | 71 | 69 | 140 |
| More than one race | 1 | 0 | 1 |
| Unknown or Not Reported | 0 | 1 | 1 |
| Foot Function Index (FFI) Total Pain Subscale Score(score on a scale) | EN3835 Group | Placebo Group | Total |
|---|---|---|---|
| Mean | 25.30 ± 5.199 | 24.84 ± 5.401 | 25.07 ± 5.291 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes
Supporting information: Study protocol, Statistical analysis plan
Ran from Nov 2021 to primary completion in Jan 2023, 13 months.
Results were first posted in Mar 2026, 3 years 2 months after primary completion. A results delay was requested in Jan 2024.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Microbial Collagenase
Fibromatosis, Plantar
Endo USA Inc., a Keenova Therapeutics Company →